Several Big Pharmas took home trophies at the annual Fierce Pharma Marketing Awards on Wednesday night. | Several Big Pharmas took home trophies at the annual Fierce Pharma Marketing Awards on ...

GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory ...

GSK plc GSK has announced the approval of the European Commission (EC) for the expanded use of its respiratory syncytial virus (RSV) vaccine, Arexvy, in adults aged 50-59 years. The vaccine has ...

GSK plc GSK has announced the approval of the European Commission (EC) for the expanded use of its respiratory syncytial virus (RSV) vaccine, Arexvy ... the EC granted marketing authorization ...

GSK plc GSK has announced the approval of the European Commission (EC) for the expanded use of its respiratory syncytial virus (RSV) vaccine, Arexvy, in adults aged ... Earlier this month, the EC ...

GSK plc (LSE/NYSE: GSK) has received approval from the European Commission to extend the use of its respiratory syncytial virus (RSV) vaccine, Arexvy, to adults aged 50-59 at increased risk of ...